Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Resmed (NYSE: RMD) announced that Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at approximately 10:30 a.m. PST in San Francisco.
The company said a live, audio-only webcast will be available via the investor website investor.resmed.com. An audio replay will be posted about 24 hours after the live event and remain accessible for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RMD gained 0.99%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Medical Instruments & Supplies showed mixed moves (e.g., ALC up 0.27%, WST up 1.47%, BDX down 0.34%), suggesting today’s modest -0.57% move in RMD is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Product clearance | Positive | -2.5% | FDA clearance for AI-enabled Smart Comfort CPAP personalization feature. |
| Oct 30 | Earnings release | Positive | -0.5% | Q1 FY26 results with revenue and margin expansion plus dividend and buybacks. |
| Oct 09 | Earnings preview | Neutral | -2.1% | Announcement of timing and access details for upcoming Q1 FY26 earnings call. |
| Sep 16 | Conference appearance | Neutral | -0.3% | Participation announcement for Bank of America Global Healthcare Conference 2025. |
| Sep 03 | Strategic initiative | Positive | +1.7% | Launch of Sleep Institute to advance global sleep health research and awareness. |
Recent history shows a tendency for RMD shares to trade lower or muted on positive or neutral news, including strong earnings and product clearances.
Over the last six months, ResMed has combined product innovation, financial strength, and thought-leadership. On Sep 03, it launched the Sleep Institute to address the global sleep-disorder burden. A Bank of America healthcare conference appearance followed on Sep 23, 2025. Fiscal Q1 2026 earnings on Oct 30 showed $1.336B revenue and expanding margins, yet shares were slightly down. More recently, FDA clearance for the AI-enabled Smart Comfort feature on Dec 08 also saw a negative price reaction. Today’s J.P. Morgan conference participation fits this pattern of regular investor-facing updates.
Market Pulse Summary
This announcement highlights ResMed’s upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, with a live and replayable audio webcast for investors. It extends a pattern of active conference participation following strong recent earnings and FDA clearance for its AI-enabled Smart Comfort feature. With shares trading below the 200-day MA of $253.46, investors may focus on management’s commentary around growth drivers, digital initiatives, and capital allocation during the event.
AI-generated analysis. Not financial advice.
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA.
More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following thirty (30) days.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
| For investors +1 858.221.3304 investorrelations@resmed.com | For media +1 619.510.1281 news@resmed.com |
FAQ
When will Resmed (RMD) present at the J.P. Morgan Healthcare Conference?
Who from Resmed (RMD) will speak at the January 12, 2026 presentation?
How can investors access Resmed's (RMD) live webcast on January 12, 2026?
Will a replay of Resmed's (RMD) January 12, 2026 presentation be available?
Does the announcement list the topics Resmed (RMD) will cover on January 12, 2026?
